Busato Davide相关文献与解析，生知库 | 链接生命科学的每一步

日期影响因子

The anti-glypican 1 AT101 antibody as targeting agent to effectively deliver chitosan nanobubbles to glioblastoma cells

以抗糖蛋白聚糖1 AT101抗体作为靶向剂，可有效将壳聚糖纳米泡递送至胶质母细胞瘤细胞。

期刊:Nanomedicine

影响因子:3.9

doi:10.1080/17435889.2024.2434451

Di Cintio, Federica; Argenziano, Monica; Scomparin, Anna; Capolla, Sara; Busato, Davide; Steffè, Aharon; Mangogna, Alessandro; Sblattero, Daniele; Cavalli, Roberta; Macor, Paolo; Dal Bo, Michele; Toffoli, Giuseppe

细胞生物学

发表日期：2025

文献求助收藏

Idarubicin-loaded chitosan nanobubbles to improve survival and decrease drug side effects in hepatocellular carcinoma.

载有伊达比星的壳聚糖纳米泡可提高肝细胞癌患者的生存率并减少药物副作用

期刊:Nanomedicine

影响因子:3.9

doi:10.1080/17435889.2025.2452154

Mossenta Monica, Argenziano Monica, Capolla Sara, Busato Davide, Durigutto Paolo, Mangogna Alessandro, Polano Maurizio, Sblattero Daniele, Cavalli Roberta, Macor Paolo, Toffoli Giuseppe, Dal Bo Michele

细胞生物学

发表日期：2025

文献求助收藏

Gut Microbiota-Based Immunotherapy: Engineered Escherichia coli Nissle 1917 for Oral Delivery of Glypican-1 in Pancreatic Cancer.

基于肠道微生物群的免疫疗法：工程化大肠杆菌 Nissle 1917 用于胰腺癌的 Glypican-1 口服递送

期刊:Medicina-Lithuania

影响因子:2.4

doi:10.3390/medicina61040633

Vruzhaj Idris, Gambirasi Marta, Busato Davide, Giacomin Aurora, Toffoli Giuseppe, Safa Amin

发表日期：2025

文献求助收藏

Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative Therapies

利用新型纳米技术克服肝细胞癌治疗中的耐药性：Glypican 3 作为创新疗法的有效靶点

期刊:International Journal of Molecular Sciences

影响因子:4.9

doi:10.3390/ijms231710038

Mossenta, Monica; Busato, Davide; Dal Bo, Michele; Macor, Paolo; Toffoli, Giuseppe

细胞生物学

发表日期：2022

文献求助收藏

New Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma

肝细胞癌血管生成靶向治疗的新见解

影响因子:4.4

doi:10.3390/cancers11081086

Mossenta, Monica; Busato, Davide; Baboci, Lorena; Cintio, Federica Di; Toffoli, Giuseppe; Bo, Michele Dal

细胞生物学

发表日期：2019

文献求助收藏